Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Express Scripts
Deloitte
Fish and Richardson
McKesson
Medtronic
Cipla
Teva
Farmers Insurance

Generated: November 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022527

« Back to Dashboard

NDA 022527 describes GILENYA, which is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are four patents protecting this drug and two Paragraph IV challenges. Additional details are available on the GILENYA profile page.

The generic ingredient in GILENYA is fingolimod hydrochloride. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fingolimod hydrochloride profile page.
Summary for 022527
Tradename:GILENYA
Applicant:Novartis
Ingredient:fingolimod hydrochloride
Patents:4
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 022527
Generic Entry Date for 022527*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022527
Medical Subject Heading (MeSH) Categories for 022527
Suppliers and Packaging for NDA: 022527
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GILENYA fingolimod hydrochloride CAPSULE;ORAL 022527 NDA Novartis Pharmaceuticals Corporation 0078-0607 0078-0607-15 30 CAPSULE in 1 BOTTLE (0078-0607-15)
GILENYA fingolimod hydrochloride CAPSULE;ORAL 022527 NDA Novartis Pharmaceuticals Corporation 0078-0607 0078-0607-89 7 CAPSULE in 1 CARTON (0078-0607-89)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 0.5MG BASE
Approval Date:Sep 21, 2010TE:RLD:Yes
Regulatory Exclusivity Expiration:May 11, 2021
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Regulatory Exclusivity Expiration:Nov 11, 2021
Regulatory Exclusivity Use:PEDIATRIC EXCLUSIVITY
Patent:➤ Try a Free TrialPatent Expiration:Aug 18, 2019Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Harvard Business School
US Department of Justice
Mallinckrodt
Healthtrust
Medtronic
McKinsey
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.